Dnmt3b rabbit pAb
ENT-A2612
Description
| REF | ENT-A2612 |
|---|---|
| Category | Antibody Polyclonal |
| Description | Dnmt3b rabbit pAb |
| Source | Rabbit |
| Applications | WB;IHC;IF;ELISA |
| Reactivity | Human;Chicken(testedbyourcustomer） |
| Reactivity | Human;Chicken(testedbyourcustomer） |
| Dilution | Western Blot: 1/500 – 1/2000. Immunohistochemistry: 1/100 – 1/300. Immunofluorescence: 1/200 – 1/1000. ELISA: 1/20000. Not yet tested in other applications. |
| Immunogen | The antiserum was produced against synthesized peptide derived from human DNMT3B. AA range:1-50 |
| Storage Stability | -20°C/1 year |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1 mg/ml |
| Observed Band KD | 96kD |
| Human Gene ID | 1789 |
| Human Swiss Prot Nº | Q9UBC3 |
| Subcellular Location | Nucleus . |
Other Name: DNMT3B; DNA (cytosine-5)-methyltransferase 3B; Dnmt3b; DNA methyltransferase HsaIIIB; DNA MTase HsaIIIB; M.HsaIIIB
Background: CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that DNA methylation is required for mammalian development. This gene encodes a DNA methyltransferase which is thought to function in de novo methylation, rather than maintenance methylation. The protein localizes primarily to the nucleus and its expression is developmentally regulated. Mutations in this gene cause the immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome. Eight alternatively spliced transcript variants have been described. The full length sequences of variants 4 and 5 have not been determined. [provided by RefSeq, May 2011],